BioSpace News Archive

Sage Therapeutics, Inc. announced that the Company will present at the following upcoming investor conferences in May: BofA Securities 2023 Health Care Conference : presentation on Wednesday, May 10, 2023 at 2:20 p.m. PT.

ImmunoGen Inc. (Nasdaq: IMGN) today announced positive top-line data from the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE® (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy.

ADMA Biologics, Inc. today announced that it will report first quarter 2023 financial results on May 10, 2023, after the U.S. financial markets close.

OraSure Technologies, Inc. has scheduled its regular earnings conference call covering 2023 first quarter financial results and certain business developments for 5:00 p.m. ET on Wednesday, May 10, 2023.

Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN) to evaluate the use of Sernova’s Cell Pouch System™ in combination with AstraZeneca’s novel therapeutic cells.

Ginkgo Bioworks today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2023.

Avantor, Inc. announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the BofA Securities 2023 Health Care Conference in Las Vegas on Tuesday, May 9, 2023 at approximately 8:00 a.m. Pacific Time.

Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and H&T Presspart have entered in a strategic partnership to advance the development of Presspart’s Sunriser© Capsule-based Dry Powder Inhaler platform.

Exscientia plc (Nasdaq: EXAI) today announced the appointment of Professor Franziska Michor, Ph.D. to its Board of Directors.

Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2023 financial results.